Sort   by:  
 Page size 
ProteomicsAfBPP of Navtemadlin probes in SJSA-1 cells
Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD058033 | Pride
Navtemadlin Sjsa-1 Afbpp 
ProteomicsAfBPP of Navtemadlin probes in MCF-7 cells
Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD058036 | Pride
Navtemadlin Mcf-7 Afbpp 
ProteomicsComparison of SJSA-1 and MCF-7 whole proteome after Navtemadlin treatment
Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we compare the whole proteme of MCF-7 and SJSA-1 cells following Navtemadlin treatment in order to gain ...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD058081 | Pride
Whole proteome Navtemadlin Sjsa-1 Mcf-7 
ProteomicsWhole proteome experiment to validate treatment conditions in SJSA-1 cells
Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD058047 | Pride
Sjsa-1 Whole proteome Navtemadlin 
ProteomicsWhole proteome experiment to validate treatment conditions in MCF-7 cells
Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD058050 | Pride
Whole proteome Navtemadlin Mcf-7 
UnknownAffinity-based protein profiling of MDM2 inhibitor Navtemadlin.
Not available
S-EPMC11921932 | biostudies-literature
TranscriptomicsWindow of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
To investigate the effectiveness of p53 reactivation in treating glioblastoma, we conducted a surgical window-of-opportunity trial (NCT03107780) of the MDM2 inhibitor navtemadlin (KRT-232) on 21 patients and determined achievable drug concentrations within tumor tissue and biological mechanisms of r...
ORGANISM(S): Homo sapiens 
2025-01-22 | GSE280891 | GEO
TranscriptomicsWindow of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma [patients]
To investigate the effectiveness of p53 reactivation in treating glioblastoma, we conducted a surgical window-of-opportunity trial (NCT03107780) of the MDM2 inhibitor navtemadlin (KRT-232) on 21 patients and determined achievable drug concentrations within tumor tissue and biological mechanisms of r...
ORGANISM(S): Homo sapiens 
2025-01-22 | GSE280951 | GEO
GenomicsWindow of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma [patients]
Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma [patients]
PRJNA1181519 | ENA
GenomicsWindow of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
PRJNA1180994 | ENA
Sort   by:  
 Page size